Skip to main content

Table 3 Univariate and Multivariate Analysis of YAP1/FAPα and Clinical Characteristics for Overall Survival of NPC Patients

From: Epstein-Barr viral product-containing exosomes promote fibrosis and nasopharyngeal carcinoma progression through activation of YAP1/FAPα signaling in fibroblasts

YAP1

Univariate analysis

 

Multivariate analysis

 

n = 106

HR (95% CI)

p value

HR (95% CI)

p value

YAP1 Score (≥80 vs. < 80)

1.447 (0.782–2.679)

0.239

2.402 (1.218–4.737)

0.011

Treatment Daysa

1.074 (0.999–1.156)

0.053

1.142 (1.049–1.242)

0.002

BEDa

0.982 (0.882–1.093)

0.737

0.887 (0.791–0.995)

0.04

Age Group (≥48 vs. < 48)

1.086 (0.587–2.009)

0.792

0.632 (0.288–1.389)

0.253

Gender (Male vs. Female)

2.412 (1.014–5.738)

0.046

3.657 (1.356–9.862)

0.01

T-Stage (T3/4 vs. T1/2)

1.956 (1.034–3.701)

0.039

3.584 (1.579–8.139)

0.002

N-Stage (N2/3 vs. N0/1)

1.394 (0.752–2.582)

0.291

1.554 (0.787–3.069)

0.204

Chemotherapy (Yes vs. No)

0.901 (0.449–1.911)

0.77

1.180 (0.515–2.706)

0.696

Comorbidity (Yes vs. No)

1.923 (1.041–3.551)

0.037

3.277 (1.493–7.190)

0.003

Smoking (Yes vs. No)

1.417 (0.756–2.658)

0.277

0.945 (0.453–1.971)

0.879

Betel quid (Yes vs. No)

1.707 (0.870–3.348)

0.12

0.980 (0.408–2.355)

0.964

Alcohol (Yes vs. No)

1.361 (0.733–2.527)

0.329

1.286 (0.588–2.812)

0.528

FAPα

Univariate analysis

 

Multivariate analysis

 

n = 143

HR (95% CI)

p value

HR (95% CI)

p value

FAPα Score (≥80 vs. < 80)

1.248 (0.890–2.259)

0.463

1.009 (0.521–1.953)

0.979

Treatment Daysa

1.044 (0.988–1.103)

0.129

1.039 (0.978–1.104)

0.212

BEDa

1.007 (0.939–1.081)

0.837

0.965 (0.887–1.049)

0.403

Age Group (≥48 vs. < 48)

1.456 (0.804–2.635)

0.215

1.340 (0.691–2.596)

0.386

Gender (Male vs. Female)

1.338 (0.681–2.631)

0.398

1.364 (0.623–2.990)

0.437

T-Stage (T3/4 vs. T1/2)

2.610 (1.403–4.855)

0.002

3.324 (1.603–6.894)

0.001

N-Stage (N2/3 vs. N0/1)

1.313 (0.738–2.338)

0.354

1.257 (0.672–2.351)

0.474

Chemotherapy (Yes vs. No)

0.766 (0.401–1.463)

0.419

0.525 (0.243–1.133)

0.101

Comorbidity (Yes vs. No)

1.432 (0.797–2.570)

0.23

1.686 (0.872–3.263)

0.121

Smoking (Yes vs. No)

1.046 (0.587–1.864)

0.878

0.893 (0.437–1.824)

0.757

Betel quid (Yes vs. No)

1.555 (0.831–2.909)

0.167

1.837 (0.867–3.893)

0.112

Alcohol (Yes vs. No)

0.978 (0.523–1.831)

0.946

0.716 (0.327–1.568)

0.404

  1. acontinuous variable. BED Biologically effective dose, HR Hazard ratio, CI Confidence interval